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Apolipoprotein A-IV (apoA-IV) has been observed to be associated with lipids, kidney function, 
adiposity- and diabetes-related parameters. To assess the causal relationship of apoA-IV with these 
phenotypes, we conducted bidirectional Mendelian randomization (MR) analyses using publicly 
available summary-level datasets from GWAS consortia on apoA-IV concentrations (n = 13,813), 
kidney function (estimated glomerular filtration rate (eGFR), n = 133,413), lipid traits (HDL cholesterol, 
LDL cholesterol, triglycerides, n = 188,577), adiposity-related traits (body-mass-index (n = 322,206), 
waist-hip-ratio (n = 210,088)) and fasting glucose (n = 133,010). Main analyses consisted in inverse-
variance weighted and multivariable MR, whereas MR-Egger regression and weighted median 
estimation were used as sensitivity analyses. We found that eGFR is likely to be causal on apoA-IV 
concentrations (53 SNPs; causal effect estimate per 1-SD increase in eGFR = −0.39; 95% CI = [−0.54, 
−0.24]; p-value = 2.4e-07). Triglyceride concentrations were also causally associated with apoA-IV 
concentrations (40 SNPs; causal effect estimate per 1-SD increase in triglycerides = −0.06; 95% 
CI = [−0.08, −0.04]; p-value = 4.8e-07), independently of HDL-C and LDL-C concentrations (causal 
effect estimate from multivariable MR = −0.06; 95% CI = [−0.10, −0.02]; p-value = 0.0014). Evaluating 
the inverse direction of causality revealed a possible causal association of apoA-IV on HDL-cholesterol 
(2 SNPs; causal effect estimate per one percent increase in apoA-IV = −0.40; 95% CI = [−0.60, −0.21]; 
p-value = 5.5e-05).
Apolipoprotein A-IV (apoA-IV) has been discussed as a biomarker and /or risk factor for cardiovascular diseases, 
kidney disease and diabetes1–4. Whether a measurable trait is a causal risk factor or a marker acting as an indi-
cator for the presence of a disease or its severity, is one of the key questions in biomedical research5, 6. To act as a 
biomarker for a certain disease, causality is not strictly required, since a biomarker can be regulated as a response 
to a disease and/or an associated trait already in a very early stage of the disease. It can therefore act as a disease 
predictor without being causally involved in the pathogenesis of the disease. Moreover, the association between a 
biomarker and a disease may be confounded by measured or unmeasured factors that distort their relationship. 
However, establishing causality between a measurable trait and a disease is crucial to understand the pathophys-
iological mechanisms.
Disease endpoints are often detected using continuous surrogate markers (e.g. fasting glucose as marker for 
impaired glucose metabolism leading to diabetes) or are influenced by many other intermediate phenotypes, 
which might better represent the causal pathway leading to a disease than the disease state itself. With this moti-
vation in mind, we evaluated the causal relation of apoA-IV with disease-related, continuous surrogate markers 
and intermediate phenotypes for which evidence from observational association studies or functional experi-
ments proposes a functional link with apoA-IV.
ApoA-IV is a glycoprotein, which is a component of triglyceride-rich and high-density lipoproteins but it 
also circulates free in human plasma7. Its physiological role is not fully elucidated, yet. It participates in reverse 
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cholesterol transport8, 9 and plays an important role in relieving peripheral cells of an overload of cholesterol10, 11. 
It has anti-atherogenic properties12, 13 and low concentrations were found to be associated with cardiovascu-
lar outcomes such as coronary heart disease or acute coronary syndrome2, 14–16. About 30% of the phenotypic 
variance has been shown to be genetically regulated17. In a recent genome-wide association study (GWAS) 
meta-analysis we have identified two variants within the APOA5-A4-C3-A1 cluster and one variant in the KLKB1 
gene to be associated with apoA-IV concentrations17. Furthermore, the lead APOA4-SNP was shown to be asso-
ciated with HDL cholesterol (HDL-C) concentrations. Other variants within the APOA5-A4-C3-A1 cluster have 
also been shown to be associated both with HDL-C, but also with triglyceride (TG) concentrations18–20. In addi-
tion, a TG genetic score was found to be associated with apoA-IV concentrations17. Studies in animal models, 
genetic association studies and studies evaluating disease progression argue for apoA-IV as the driving factor 
influencing satiety, adiposity, glucose concentrations and chronic kidney disease21–28. On the other hand apoA-IV 
concentrations have also been shown to change following food intake, gastric bypass surgery or weight loss29, 30. 
Those findings warrant further investigation in causal associations and especially in the direction of the effects 
between apoA-IV and lipid levels, adiposity, diabetes-related parameters and kidney function. Recent develop-
ments in genetic epidemiology using genetic markers as proxies for a trait help estimate causal associations with 
a disease outcome through a Mendelian randomization approach31.
Such causal effects are usually very small. Therefore, single studies are often underpowered. However, results 
of genome-wide association studies are increasingly made publicly available. Harnessing summary-level data, 
Mendelian randomization analyses then reach sufficient statistical power to yield more precise causal effect 
estimates32.
For all of the already mentioned apoA-IV-associated and disease-related traits, large genome-wide associa-
tion studies are available, in which dozens of genetic variants have been identified18, 33–36. Furthermore, a GWAS 
meta-analysis on apoA-IV concentrations has been published recently17.
Therefore, we conducted a bidirectional two-sample Mendelian randomization analysis to assess the causal 
relationship of apoA-IV concentrations with HDL-C, LDL cholesterol (LDL-C), TG, fasting glucose (FG) as 
well as body-mass-index (BMI), waist-hip-ratio adjusted for BMI (WHR), and estimated glomerular filtration 
rate (eGFR). Herein, lipid levels, adiposity-related traits, glucose and eGFR were considered as risk factors on 
apoA-IV concentrations as outcome variable. We complemented the analysis by investigating the inverse associ-
ation of whether apoA-IV is causally associated with the same traits. We applied different sensitivity analyses to 
account for presence of potential pleiotropy.
Results
Validity of instrumental variables and power analysis. A graphical overview of the design and studies 
used in our investigation is given in Fig. 1. To assess the strength of the instrumental variables (i.e. the single-nu-
cleotide polymorphisms [SNPs]) that were used for the Mendelian Randomization, the explained variance (R²) 
defined by the SNPs is given for each of the investigated potential risk factors in Tables 1 and 2. R² varies between 
0.0060 (WHR) and 0.0727 (LDL-C).
Table 1 shows, which fraction of detectable causal R² of the exposure trait on the outcome (i.e. which magni-
tude of causal effect of the trait on the outcome) can be detected for the calculated R² of the genetic variants on 
the exposure (for HDL-C to fasting glucose as the exposure trait, apoA-IV is the exposure and for apoA-IV as 
the exposure trait, the other investigated traits function as the outcome). It varies between 0.0127 for LDL-C and 
0.1544 for WHR, assuming a significance level of α = 0.00625 and a power of 80%. That is, to detect a causal effect 
of WHR on apoA-IV, WHR would have to explain more than 15% of the phenotypic variance of apoA-IV. For the 
Figure 1. Graphical overview of the study design. Seven biomarkers out of four consortia (GLGC18; CKDGen 
consortium33; GIANT consortium34, 60; MAGIC35, 36) were included as well as results from a GWAS meta-
analysis on apoA-IV17.
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reverse causation (effect of apoA-IV on the other factors), causal effects ranging between 0.002 and 0.0048 would 
be detectable (Table 2).
Mendelian randomization analyses. Causal association of lipid traits on apoA-IV. An overview 
about the characteristics and the meta-analysis results of the 71 HDL-SNPs, the 58 LDL-SNPs and the 40 
triglyceride-SNPs can be found in Supplementary Tables 1–3.
Using the MR-IVW method revealed a significant association of HDL-C levels (in SD) with the 
log-transformed apoA-IV concentrations resulting in a causal estimate of βMR-IVW = 0.0341 (95% CI = [0.0142, 
0.0540], p-value = 0.0008, Table 3 and Fig. 2). This means an increase in one SD in HDL-C levels (≈17 mg/dL) 
leads to an increase of the log-transformed apoA-IV levels of approximately 0.034, which corresponds to a rel-
ative increase of 3.4%. After adjusting for LDL-C as well as TG in the multivariable Mendelian randomization 
using all 71 SNPs, this causal effect diminished and became non-significant (βadjusted = 0.0195, 95% CI = [−0.0084, 
0.0475], p-value = 0.1706, see Table 3). One SNP was identified to be potentially pleiotropic by the gtx-package in 
R (rs964184 within the gene region APOA5-A4-C3-A1). This is the same SNP that we planned to exclude as a sen-
sitivity analysis due to its close proximity to the APOA4 gene (see Methods). After exclusion of this SNP, the effect 
became non-significant (βMR-IVW_gtx = 0.0271, 95% CI = [0.0067, 0.0474], p-value = 0.0091, see Table 3). By adjust-
ing for LDL-C and TG, the beta estimate remained approximately the same and was non-significant, too (Table 3). 
Excluding the 23 SNPs that were in LD with SNPs associated with any of the other traits (Supplementary Table 8) 
and applying the MR-IVW method to the remaining 48 SNPs did not change the causal estimate obtained using 
all 71 SNPs, but it became non-significant (p = 0.0453, Supplementary Table 15 and Supplementary Figure 4). The 
application of the multivariable Mendelian randomization approach to the 61 SNPs not in LD with SNPs from the 
non-lipid traits gave comparable results to using the adjustment model on all 71 SNPs (p = 0.1212, Supplementary 
Table 15 and Supplementary Figure 5). Using the MR-Egger regression method resulted in a markedly higher 
and statistically significant causal effect of βMR-Egger = 0.0611 (95% CI = [0.0254, 0.0969], p-value = 0.0008, see 
Supplementary Table 16, Supplementary Figure 15), but also with a broader confidence interval. However, 
when using a weighted median estimation approach, the causal effect diminished and became non-significant 
(Supplementary Table 16).
For LDL-C levels, we obtained a significant causal estimate of βMR-IVW = −0.0376 (95% CI = [−0.0572, 
−0.0179], p-value = 0.0002, Table 3 and Fig. 3) by using the MR-IVW method. This means that LDL-C levels 
and the log-transformed apoA-IV concentrations are inversely correlated and an increase in LDL-C will result in 
a decrease of apoA-IV levels. Adjusting for HDL-C as well as TG in the multivariable Mendelian randomization 
using all 58 SNPs reduced the size of the causal effect estimate and it became non-significant (βadjusted = −0.0225, 
95% CI = [−0.0441, −0.0010], p-value = 0.0406, see Table 3). Using the gtx-package in R, no heterogeneous 
SNP could be detected. After exclusion of the above mentioned SNP rs964184 and application of the MR-IVW 
method based on the remaining 57 SNPs, we obtained a significant causal estimate comparable to the MR-IVW 
Phenotype 
(Exposure trait)
No. of 
SNPs
N exposure 
dataset
N outcome 
dataset
R² of SNPs on 
exposure in %
Detectable R2 of exposure 
on outcome in %*
HDL-C 71 188,577 13,813 6.76 1.37
LDL-C 58 188,577 13,813 7.27 1.27
TG 40 188,577 13,813 3.25 2.85
eGFR 53 133,413 13,813 3.22 2.88
BMI 77 322,206 13,813 2.41 3.84
WHR 40 210,088 13,813 0.60 15.44
Fasting Glucose 36 133,010 13,813 3.57 2.60
Table 1. Strength of instrumental variables used for the MR analyses: Explained variance (R²) of SNPs on the 
different exposure traits and detectable causal explained variance (R2) of the exposure traits on apoA-IV as 
outcome. *Power = 80%; significance level α = 0.00625; sample size n = N outcome dataset.
Phenotype 
(Outcome trait)
No. of 
SNPs
N exposure 
dataset
N outcome 
dataset
R² of SNPs on 
exposure in %
Detectable R2 of exposure 
on outcome in %*
HDL-C 2 16,080 188,577 2.00 0.34
LDL-C 2 16,080 188,577 2.00 0.34
TG 2 16,080 188,577 2.00 0.34
eGFR 2 16,080 133,413 2.00 0.48
BMI 2 16,080 322,206 2.00 0.20
WHR 2 16,080 210,088 2.00 0.30
Fasting Glucose 3 16,080 133,010 2.90 0.48
Table 2. Strength of instrumental variables used for the MR analyses: Explained variance (R²) of SNPs on 
apoA-IV as exposure trait and detectable causal explained variance (R2) of apoA-IV as exposure trait on the 
different outcomes. *Power = 80%; significance level α = 0.00625; sample size n = N outcome dataset.
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estimate we got using all 58 SNPs (Table 3). By adjusting for HDL-C and TG, the beta estimate remained nearly 
the same but it became non-significant βadjusted = −0.0259 (95% CI = [−0.0480, −0.0039], p-value = 0.0213, see 
Table 3). Excluding the 12 SNPs that were in LD with SNPs associated with any of the other traits (Supplementary 
Table 9) and applying the MR-IVW method to the remaining 46 SNPs did not markedly change the causal 
estimate obtained using all 58 SNPs, but it became non-significant (p = 0.0144, Supplementary Table 15 and 
Supplementary Figure 6). The application of the multivariable Mendelian randomization approach to the 57 
SNPs not in LD with SNPs from the non-lipid traits gave comparable results to using the adjustment on all 58 
SNPs (p = 0.0395, Supplementary Table 15 and Supplementary Figure 7). Using MR-Egger regression and the 
weighted median estimation method, LDL-C remained associated with apoA-IV (Supplementary Table 16 and 
Supplementary Figure 16).
Taking the 40 SNPs associated with triglyceride levels and using the MR-IVW method, a significant causal 
estimate of βMR-IVW = −0.0600 (95% CI = [−0.0834, −0.0366], p-value = 4.80 × 10−7, Table 3 and Fig. 4) was 
obtained. As for LDL-C levels, an increase in TG levels will result in a decrease of apoA-IV concentrations. 
Adjusting for HDL-C and LDL-C in the multivariable MR resulted in nearly the same statistically significant 
Phenotype (exposure)
Causal effect of phenotype on apoA-IV
All SNPs Removing SNP rs964184 for lipids
No. of SNPs Beta* 95% CI* P-value No. of SNPs Beta* 95% CI* P-value
Lipid traits
HDL-C, unadjusted 71 0.0341 [0.0142, 0.0540] 0.0008 70 0.0271 [0.0067, 0.0474] 0.0091
HDL-C, adjusted for LDL-C 
and TG (multivariable MR) 71 0.0195 [−0.0084, 0.0475] 0.1706 70 0.0262 [−0.0018, 0.0542] 0.0672
LDL-C, unadjusted 58 −0.0376 [−0.0572, −0.0179] 0.0002 57 −0.0320 [−0.0519, −0.0121] 0.0016
LDL-C, adjusted for HDL-C 
and TG (multivariable MR) 58 −0.0225 [−0.0441, −0.0010] 0.0406 57 −0.0259 [−0.0480, −0.0039] 0.0213
TG, unadjusted 40 −0.0600 [−0.0834, −0.0366] 4.8e-07 39 −0.0498 [−0.0776, −0.0220] 0.0004
TG, adjusted for HDL-C and 
LDL-C (multivariable MR) 40 −0.0597 [−0.0962, −0.0232] 0.0014 39 −0.0487 [−0.0883, −0.0090] 0.0161
Kidney function
eGFR 53 −0.3890 [−0.5367, −0.2413] 2.4e-07
Adiposity-related parameters
BMI 77 0.0067 [−0.0266, 0.0400] 0.6946
WHR 40 0.0761 [0.0093, 0.1429] 0.0255
Fasting Glucose
Fasting Glucose 36 0.0146 [−0.0364, 0.0656] 0.5742
Table 3. MR-IVW estimates for all phenotypes assumed to causally affect the apoA-IV concentrations. Here, 
the phenotypes act as exposures and apoA-IV as the outcome. A p-value smaller than 0.05/8 = 0.00625 is 
considered to be significant (marked in bold). *In log(apoA-IV) per change in SD for the lipid and obesity 
traits, in log(apoA-IV) per change in log(eGFR) for kidney function, in log(apoA-IV) per change in mmol/L for 
fasting glucose.
Figure 2. Scatterplot showing the effect estimates of SNP-HDL-C (high-density lipoprotein cholesterol) 
associations (95% CI) on the x- and SNP-apoA-IV (apolipoprotein A-IV) associations (95% CI) on the y-axis 
for all 71 SNPs. The continuous black line represents the MR-IVW estimate of HDL-C on apoA-IV (dashed 
lines represent corresponding 95% CI). The SNP rs964184 (ZPR1, formerly known as ZNF259), which was 
identified to be potentially pleiotropic is marked in red.
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causal estimate (βadjusted = −0.0597, 95% CI = [−0.0962, −0.0232], p-value = 0.0014, see Table 3). By applying 
the gtx-package in R, no heterogeneous SNP could be detected. Excluding the 23 SNPs that were in LD with 
SNPs associated with any of the other traits (Supplementary Table 10) and applying the MR-IVW method to the 
remaining 17 SNPs did not change the causal estimate obtained using all 40 SNPs, but it became non-significant 
(p = 0.1003, Supplementary Table 15 and Supplementary Figure 8). The application of the multivariable 
Mendelian randomization approach to the 33 SNPs not in LD with SNPs from the non-lipid traits resulted in a 
significant causal estimate comparable to the estimate obtained using the adjustment on all 58 SNPs (p = 0.0047, 
Supplementary Table 15 and Supplementary Figure 9). All other sensitivity analyses, i.e. the exclusion of SNP 
rs964184 as well as the application of the MR-Egger regression or the weighted median estimation method 
resulted all in nearly the same statistically significant causal estimate (Table 3 and Supplementary Table 16). 
Looking at the funnel plot and the individual SNP-based contributions to the MR analysis, the causal estimate of 
one SNP (rs838880, within SCARB1) attracted our attention as it harbored a potential bias due to its low level of 
precision (Supplementary Figure 17). However, excluding this SNP from the MR-IVW analysis as well as from the 
MR-Egger regression analysis did not change the overall causal estimate as the precision of this one IV estimate 
was very low (data not shown).
Concerning directional pleiotropy, MR-Egger intercepts did not depart significantly from the origin for all 
investigated lipid traits, meaning that no directional bias could be detected in all cases (Supplementary Table 17). 
Assessment of the NOME assumption gave I²GX = 0.98 for all investigated lipid traits, suggesting an approximate 
2% attenuation of the causal estimate towards zero due to measurement error in the exposure trait. The bias 
adjustment via SIMEX did not change the causal MR-Egger estimate noticeably (Supplementary Table 18).
Figure 3. Scatterplot showing the effect estimates of SNP-LDL-C (low-density lipoprotein cholesterol) 
associations (95% CI) on the x- and SNP-apoA-IV (apolipoprotein A-IV) associations (95% CI) on the y-axis 
for all 58 SNPs. The continuous black line represents the MR-IVW estimate of LDL-C on apoA-IV (dashed 
lines represent the corresponding 95% CI). The SNP rs964184 (ZPR1, formerly known as ZNF259), which was 
excluded in a sensitivity analysis is marked in red.
Figure 4. Scatterplot showing the effect estimates of SNP-TG (triglycerides) associations (95% CI) on the x- 
and SNP-apoA-IV (apolipoprotein A-IV) associations (95% CI) on the y-axis for all 40 SNPs. The continuous 
black line represents the MR-IVW estimate of TG on apoA-IV (dashed lines represent the corresponding 95% 
CI). The SNP rs964184 (ZPR1, formerly known as ZNF259), which was excluded in a sensitivity analysis is 
marked in red.
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Causal association of kidney function (eGFR) on apoA-IV. An overview about the characteristics and the 
meta-analysis results of the 53 SNPs found to be associated with eGFR can be found in Supplementary Table 4. 
Using the MR-IVW method for analyzing the influence of kidney function on the log-transformed apoA-IV 
concentrations resulted in a statistically significant causal estimate of βMR-IVW = −0.3890 (95% CI = [−0.5367, 
−0.2413], p-value = 2.44 × 10−7, see Table 3 and Fig. 5). Consequently, an increase in eGFR will reduce the 
apoA-IV concentrations. Using the gtx-package in R, no heterogeneous SNP could be detected. Excluding the 4 
SNPs that were in LD with SNPs associated with any of the other traits (Supplementary Table 11) and applying the 
MR-IVW method to the remaining 49 SNPs did not change the causal estimate obtained using all 53 SNPs at all 
(Supplementary Table 15 and Supplementary Figure 10). The causal estimate obtained using MR-Egger regression 
gave an even higher significant effect and the significant weighted median estimate was between the other two 
estimates in size (Supplementary Table 16 and Supplementary Figure 18).
Using the MR-Egger regression, no directional pleiotropy could be detected for the analysis of eGFR on the 
log-transformed apoA-IV concentrations (Supplementary Table 17). Assessment of the NOME assumption gave 
I²GX = 0.82, suggesting an approximate 15% to 20% attenuation of the causal estimate towards zero due to meas-
urement error in the exposure trait. Therefore, the bias adjustment via SIMEX did result in a slightly stronger 
negative effect of the corrected causal MR-Egger estimate (Supplementary Table 18).
Causal association of the adiposity-related traits and fasting glucose on apoA-IV. An overview about the character-
istics and the meta-analysis results of the 77 BMI-SNPs, the 40 WHR-SNPs and the 36 glucose-SNPs can be found 
in Supplementary Tables 5–7. All three factors did not show a significant association on the log-transformed 
apoA-IV concentrations neither by using the MR-IVW approach based on all SNPs or after excluding potentially 
pleiotropic SNPs using the proxy search (Table 3, Supplementary Tables 12–14 and Supplementary Figures 11–13) 
nor by using the MR-Egger regression or the weighted median estimation approach (Supplementary Table 16, 
Supplementary Figures 1–3 and Supplementary Figures 19–21). Using the gtx-package in R, no heterogeneous 
SNPs could be detected. The MR-Egger regression intercept estimate was non-significant for all of these variables, 
such that no directional pleiotropy could be detected (Supplementary Table 17).
Causal association of apoA-IV on the other traits. The characteristics and meta-analysis results of the 3 SNPs 
found to be associated with apoA-IV can be found in Supplementary Table 19. The investigation of apoA-IV 
as exposure on the other traits revealed only one significant finding. Two of the three SNPs that were found 
to be associated with apoA-IV were present in the HDL-C dataset. Using this data in a MR analysis using the 
MR-IVW method resulted in a significant causal estimate of βMR-IVW = −0.4017 (95% CI = [−0.5970, −0.2064], 
p-value = 5.52e-05, see Table 4). Therefore, an increase in apoA-IV will result in a decrease in HDL-C. For the 
other traits, none of the causal estimates were significant (p-values ranging between 0.0754 and 0.8930, Table 4). 
Assessment of the NOME assumption gave I²GX = 0.99, suggesting an approximate 1% attenuation of the causal 
estimate towards zero due to measurement error in the exposure trait (Supplementary Table 18). Therefore, bias 
due to measurement error in the exposure trait is negligible.
Discussion
The evaluation of the causal relations of apoA-IV with disease-related traits using Mendelian randomization 
analyses revealed three major findings: The most interesting finding was that eGFR is likely to causally influence 
apoA-IV concentrations. Furthermore, TG was found to affect apoA-IV concentrations, whereas apoA-IV con-
centrations seem to influence HDL-C.
The main Mendelian randomization analysis as well as all sensitivity analyses consistently showed that an 
increase in eGFR is associated with a decrease in apoA-IV concentrations. The investigation in the reverse direc-
tion, i.e. whether apoA-IV levels are causal on eGFR, did not result in a statistically significant finding. This was 
Figure 5. Scatterplot showing the effect estimates of SNP-eGFR (estimated glomerular filtration rate) 
associations (95% CI) on the x- and SNP-apoA-IV (apolipoprotein A-IV) associations (95% CI) on the y-axis 
for all 53 SNPs. The continuous black line represents the MR-IVW estimate of eGFR on apoA-IV (dashed lines 
represent the corresponding 95% CI).
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at the first glance surprising since prior studies found apoA-IV as a predictor of CKD progression independent 
of the GFR measured at baseline25. It has been suggested that other properties of apoA-IV not related to the fil-
tration capacity of the kidney might explain the association with CKD progression25. If apoA-IV concentrations 
change already very early in the progression of kidney impairment, apoA-IV may still serve as a valuable marker 
for kidney disease and disease progression, which has been found in earlier cross-sectional studies22–24. On the 
other hand, knowing that chronic kidney disease is intimately associated with risk of cardiovascular disease37, 
this finding is interesting to stimulate research on biological pathways that link decrease in kidney function with 
apoA-IV levels.
The second main finding was that TG causally affects apoA-IV, even after adjusting for HDL-C and LDL-C. 
However, in the sensitivity analysis excluding the potentially pleiotropic SNP rs964184, the causal effect calcu-
lated using the MR-IVW method resulted in a statistically non-significant estimate. In this setting, this was not 
surprising, as this SNP was the one with the highest effect size on both TG and log(apoA-IV). However, it is only 
mandatory to exclude this SNP from the analysis, if it violates the instrumental variable assumption. This would 
be the case, if it influenced apoA-IV concentrations directly or through an endogenous variable that is differ-
ent from the exposure. It was not identified to be pleiotropic by the applied statistical methods (gtx-package), 
though. Although being located within the APOA5-A4-C3-A1 gene cluster, this SNP is rather independent from 
the APOA4-SNPs associated with apoA-IV concentrations, as already discussed in Lamina et al.17. Rs964184 is 
located in the 3′ UTR of ZRP1 (formerly known as ZNF259), approximately 50 kb downstream of APOA4, and 
shows r2 < 0.3 with SNPs in APOA4 (according to 1000 Genomes, phase 3; Supplementary Figure 14). It presents, 
however, a moderate linkage disequilibrium with SNPs in APOA5 (max. r2 = 0.52 for rs2266788; Supplementary 
Figure 14), which is a major regulator of plasma triglyceride concentration38. Expression QTLs (eQTLs, i.e. SNPs 
associated with expression of a gene) reported in GTEx for BUD13, ZPR1 and all apolipoprotein genes in the 
APOA5-A4-C3-A1 gene cluster were not in linkage disequilibrium (LD) with rs964184 (maximum pair-wise 
LD was with eQTL rs4225 for APOA1: r2 = 0.2; D′ = 0.08; single SNP data not shown). Together this suggests 
that rs964184 is neither in LD with SNPs in the APOA4 gene nor with any known eQTL in the gene cluster, but 
presents modest LD with SNPs in APOA5. It is therefore unlikely that rs964184 has a direct effect on apoA-IV 
concentrations and it would be too conservative to exclude it from the analysis. It is also not surprising that the 
exclusion of the 23 SNPs, which are included in the SNP sets of the other traits or in LD with SNPs of the other 
traits, resulted in a non-significant causal estimate. Among these 23 SNPs were the most informative SNPs, i.e. 
SNPs with the highest effect on TG and therefore also on apoA-IV. Not even half of the triglyceride SNPs remain, 
which is primarily due to being in LD with HDL-C SNPs. The multivariable method is the most useful method 
to account for this interrelation with other lipid traits by simultaneously keeping the most informative SNPs. 
Therefore, we additionally excluded only SNPs that were in LD with SNPs from the non-lipid traits, but adjusted 
for HDL-C and LDL-C. Using this method, the causal estimate from triglycerides on apoA-IV remained statisti-
cally significant. Nevertheless, this relationship has to be interpreted with caution. Further studies are needed to 
confirm this potentially causal association of TG and apoA-IV.
The investigation of HDL-C and LDL-C as causal factors influencing apoA-IV concentrations yielded incon-
sistent results. In previous genetic studies, several loci have been associated with apoA-IV as well as HDL-C and 
LDL-C17–19. Besides, a study investigating the LDL-C lowering response to different diets found that the apoA-IV 
protein isoforms modulate the LDL-C lowering response to a diet39. However, we demonstrated recently in a 
study with more than 13,000 individuals, that the genetic variants that are the molecular basis for the apoA-IV 
isoforms do not have an effect on apoA-IV concentrations. In the data at hand, the MR-IVW method and the 
MR-Egger regression revealed a statistically significant positive causal estimate, but the effect vanished after 
adjustment for the other lipid traits. It is therefore conceivable that the effect of both HDL-C as well as LDL-C on 
apoA-IV concentrations is triggered primarily by the association with TG. Furthermore, 5 SNPs are present in 
Phenotype (outcome)
Causal effect of apoA-IV on phenotype
No. of SNPs Beta§ 95% CI§ P-value
Lipid traits
HDL-C, unadjusted 2 −0.4017 [−0.5970, −0.2064] 5.52e-05
LDL-C, unadjusted 2 0.1931 [−0.0197, 0.4059] 0.0754
TG, unadjusted 2 −0.0761 [−0.2677, 0.1154] 0.4360
Kidney function
eGFR 2 0.0207 [−0.0136, 0.0550] 0.2369
Adiposity-related parameters
BMI 2 −0.0325 [−0.1840, 0.1190] 0.6744
WHR 2 0.0119 [−0.1609, 0.1847] 0.8930
Fasting Glucose
Fasting Glucose 3 0.0462 [−0.0708, 0.1631] 0.4392
Table 4. MR-IVW estimates for all phenotypes assumed to be causally affected by apoA-IV concentrations. 
§In SD per change in log(apoA-IV) for the lipid and obesity traits, in log(eGFR) per change in log(apoA-IV) for 
kidney function, in mmol/L per change in log(apoA-IV) for fasting glucose. Here, apoA-IV acts as exposure and 
the phenotypes as the outcome traits. A p-value smaller than 0.05/8 = 0.00625 is considered to be significant 
(marked in bold).
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all three lipid datasets (rs12748152, rs964184, rs174546, rs3764261, rs2954029) which might also influence this 
result. The exploration of the reverse causation, i.e. whether apoA-IV influences HDL-C, resulted in a significant 
finding, showing an inverse causal direction. However, this result is triggered mainly by one SNP in the APOA4 
gene (rs1729407). This SNP was associated with both apoA-IV concentrations as well as HDL-C. Since it was 
the top signal in the GWAS on apoA-IV concentrations17 but not genome-wide significantly associated with 
HDL-C18, although conducted in a much higher sample size, it is conceivable that it exerts an effect primarily on 
apoA-IV. However, a direct effect on HDL-C cannot be excluded which would violate the exclusion-restriction 
assumption of Mendelian randomization. Given that apoA-IV is an important component of the HDL-C parti-
cle21, 40–42, a causal effect of apoA-IV on HDL-C level is possible and partly supported by our data, but has to be 
considered with caution.
Investigating the adiposity-related traits resulted in no significant findings. This is in contrast to the literature 
on observational epidemiological and functional studies: apoA-IV has been proposed as a satiety factor and 
related to diet-induced adiposity, both in animal models21 and in humans26. In addition, the administration of 
apoA-IV resulted in reduction of food intake and genetic association studies have found associations between 
polymorphisms within the APOA4 gene and adiposity-related traits27, 28. Although these findings argument in 
favor of apoA-IV as a risk factor, it has also been shown that apoA-IV is decreased following weight loss and/
or gastric bypass29, 30. Despite the epidemiological and also functional studies linking adiposity-related traits 
to apoA-IV, we could not find a causal effect in one or the other direction. One reason for that might be that – 
despite the already huge datasets and the high number of associated SNPs – the power is still insufficient to detect 
a causal effect from especially WHR as exposure on apoA-IV as outcome variable. To be detectable in our analysis 
with a power of 80%, the causal effect of WHR on apoA-IV would have to be that high, that it explains at least 
15% of the phenotypic variance of apoA-IV (Table 1). The detectable explained variance is in a more realistic 
range for BMI (about 3.8%), but still higher than for the other investigated phenotypes. For the other direction 
of causality (apoA-IV as exposure for adiposity), however, lack of power should not be an issue. Even such small 
effects as 0.2–0.3% of explained variance should have been possible to detect. Therefore, it is rather unlikely, that 
apoA-IV causally influences BMI or WHR. It has to be noted that the choice of WHR and BMI as factors of satiety 
might not be optimal. However, they are the most commonly used markers for adiposity, for which there is also 
sufficient information on genetic loci influencing these traits and were therefore chosen for the evaluation of 
adiposity-related traits.
Counter-intuitively, we found no causal association of fasting glucose with apoA-IV and vice versa. This should 
not be a problem of power like for the adiposity-related traits, as the effect that could be detected with the given 
data is even smaller than for TG and eGFR. Already much is known that links glucose with apoA-IV. Diabetics 
have been found to have significantly higher apoA-IV levels26, 43. Apart from that, apoA-IV was inversely associ-
ated with prediabetes (defined by fasting glucose levels) and also with 2 h glucose levels4. Experimental studies 
and APOA4 knockout mice have also shown that apoA-IV has a glucose-lowering effect29, 44. Therefore, we would 
have expected to find a causal association of the apoA-IV SNPs (where all 3 SNPs were present in the dataset from 
Manning et al.) on fasting glucose. In this case, apoA-IV would have to explain only more than 0.48% of the phe-
notypic variance of fasting glucose to have a power of 80%. Still, we could not find a causal association with any of 
the methods used in any of the investigated directions. Not finding a significant association does not exclude the 
possibility that there still exists one: apoA-IV and fasting glucose might still be causally related with each other 
but the true effect might be smaller than what can be detected with our data. The other possibility to explain this 
non-significant finding might be that the observed association of apoA-IV with glucose is confounded by other 
factors that influence both traits.
Using summary-level data of all SNPs that have been shown to be genome-wide significantly associated with 
their respective traits as instrumental variables, is both a strength but also a limitation of our study. By using 
summarized data, a higher power can be achieved than in single studies. The availability of dozens of associ-
ated SNPs that were identified in more than 100,000 participants does not guarantee to get a high power for the 
Mendelian randomization analysis, though. For the adiposity-related traits as risk/protective factors for apoA-IV, 
the instrumental variables do not explain much of the variation in these traits. Therefore, to be able to find a 
causal association of a reasonable size, further SNPs would have to be identified that can be used to increase the 
variance explained on BMI and especially WHR. For the lipid traits, however, our applied methods based on 
summarized data achieved a high power enabling the detection of very low causal effects. Nevertheless, not only 
high power is necessary for Mendelian randomization analysis but also the choice of valid instruments. To be a 
valid instrumental variable, a SNP should be associated only with the respective risk/protective factor. For the 
correlated traits HDL-C, LDL-C and TG, there is substantial overlap of the SNPs, which makes it extremely diffi-
cult to discriminate the instrumental variables for each of the lipid traits correctly from each other. The exclusion 
of all instrumental variables that were found to be associated with at least two of the three lipid traits would lead 
to a substantial loss of strength for the Mendelian randomization analyses. However, we checked for possible 
pleiotropy of the SNPs using appropriate statistical methods and adjusted for the effects of the other lipid traits to 
find independent causal effects. Still, the interpretation of the identified causal effects remains difficult.
Another limitation which arises from using summary-level data is that observed effect sizes cannot be derived 
from directly and thus, if not obtainable from the literature, cannot be compared with the estimated causal effects. 
Although we only investigated causal relationships for which there is already sufficient evidence of either obser-
vational association or functional experiments, direct comparison of observational and causal estimate is only 
possible if it is on the same scale. All GWAS meta-analysis data we used for our analyses are derived from either 
log-transformation or inverse normal transformation. However, such transformations are hardly ever done in 
observational epidemiological studies. Results from functional wet-lab experiments can certainly not be trans-
ferred into observational estimates.
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To summarize, our data revealed an inverse causal association of kidney function (eGFR) on apoA-IV. 
Furthermore, investigating the lipid traits suggested a causal involvement of primarily triglyceride levels on 
apoA-IV concentrations. The causal effects of HDL-C and LDL-C on apoA-IV are hard to discriminate from each 
other and from the effects triggered by TG. Our results also argue for a causal, inverse association of apoA-IV 
concentrations on HDL-C, which however have to be interpreted with caution due to potential presence of plei-
otropic effects of the genetic markers.
Methods
Data sources and SNP selection.  For all evaluated disease-related traits and apoA-IV, SNPs were selected 
and summarized results were taken from the most recent and most comprehensive GWAS, which were conducted 
primarily in cohorts of European ancestry. A graphical overview of the design and studies used in our investiga-
tion is given in Fig. 1. A fraction of the five studies which have been included in the apoA-IV-GWAS meta-anal-
ysis have also been part of the GWAS meta-analyses of the other parameters (lipids, eGFR, adiposity-related 
parameters and fasting glucose). The overlap of samples ranges between 19% and 80%. Details on the data sources 
and SNP selection can be found in the Supplementary material.
Measurement of apoA-IV. For all participating studies, quantification of plasma apoA-IV was done in the 
same laboratory (Division of Genetic Epidemiology, Medical University of Innsbruck, Austria). It was based on 
a double-antibody enzyme-linked immunosorbent assay using an affinity-purified polyclonal rabbit anti-human 
apoA-IV antibody for coating and the same antibody coupled to horseradish peroxidase for detection. Plasma 
with a known concentration of apoA-IV was used as the calibration standard45. Four control sera with different 
concentrations were run on each plate in double measurements for control purposes throughout the entire pro-
ject. The intra- and interassay coefficients of variation were 2.7% and 6.0%, respectively45.
Statistical Methods
Validity of instrumental variables and power analysis. In Mendelian randomization analyses, instru-
mental variables should meet certain requirements to minimize weak instrument bias.
The strength of the instrumental variables (SNPs) used for the Mendelian randomization analysis was assessed 
using the explained variance (R²). R² was calculated according to Pattaro et al.33. Using this formula, the percentage 
of phenotypic variance explained by the instrumental variables (SNPs) can be estimated as = ∑ =R Rik i
2
1
2, where 
β=R var SNP var X( )/ ( )i i i
2 2  is the coefficient of determination for all k SNPs associated with the potential risk factor/
exposure X, βi is the estimated effect of the ith SNP on the risk factor X, = × × −( )var SNP MAF MAF( ) 2 1i SNP SNPi i  
and var X( ) is the variance of the potential risk factor X ( =var X( ) 1 for the lipid and adiposity traits, since the beta 
estimates refer to change in 1 standard deviation (SD)).
The F-statistic is typically used to judge on the validity of instrumental variables. However, it cannot be calcu-
lated in this setting, where only summary-level data are available. However, only genome-wide significant SNPs 
that are independent from each other (pairwise LD between all SNPs: r2 < 0.1) were included in this analysis 
(p-value < 5 × 10−8). This corresponds to an F statistic > 30 for each single variant46. In the Mendelian random-
ization literature a threshold of F < 10 has typically been used to define a “weak IV” (the Staiger-Stock rule47, 48). 
Since we are using a combination of several genome-wide significant SNPs, weak instrument bias is negligble.
Power calculations were carried out using the online tool https://sb452.shinyapps.io/power/. The power can-
not be calculated directly as different units were used for the different traits and only summary-level data are 
available. Therefore, a rough approximation for all investigated traits was performed based on standardized val-
ues. The applied online tool was rather meant for Mendelian randomization methods based on individual-level 
data. However, as shown in ref. 49, analyses based on individual level data and summarized data methods are 
comparable with respect to power.
The sample size assumed for the power analysis is set to the sample size of the outcome dataset, since the ratio 
estimate involves the variance of the outcome dataset, but not the variance of the exposure dataset. Therefore, the 
sample size was set to 13,800 for apoA-IV as the outcome variable. For the power-analysis of the reverse causation 
(apoA-IV as exposure on the various phenotypes), a sample size of 188,577 is assumed for the lipid analysis etc. 
(Table 2). Given R2 of the genetic variants on the exposure, the sample size, the desired power (80%) and the sig-
nificance level, it can be calculated which causal effect estimate can be detected with the given data, if it is truly 
there. This detectable causal estimate βcausal is based on change in one SD of the outcome per one SD change in 
exposure. In this setting βcausal
2  is equal to the variance explained (Rcausal
2 ) of the exposure variable on the outcome. 
Therefore, we can answer the question, which strength of causal association we can most likely detect with the 
given data.
Mendelian randomization methods. The Mendelian randomization analyses were performed bidi-
rectional. In the first run, apoA-IV was considered as an outcome variable whereas lipids, eGFR, BMI, WHR 
(adjusted for BMI) and fasting glucose levels were considered as exposures. In the second run, apoA-IV was the 
exposure variable and the other phenotypes (lipids, eGFR, BMI, WHR (adjusted for BMI) and fasting glucose 
levels) were used as outcomes.
Before any analysis, the SNP-exposure and SNP-outcome association estimates have all been oriented towards 
an increase in the exposure trait.
For the main Mendelian randomization analysis, the SNP-exposure and SNP-outcome estimates were com-
bined using the inverse-variance weighted (MR-IVW) method as proposed by Burgess et al.46. Causal estimates 
based on this method are notated as βMR-IVW. The MR-IVW estimate can also be interpreted as a weighted regres-
sion from the effect estimates of the exposure SNPs on the estimates of the outcome of the same SNPs (removing 
the intercept).
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As the MR-IVW method assumes that all genetic variants satisfy the IV assumptions (including no pleiotropy 
of all included SNPs, and No Measurement Error (NOME) in the gene-exposure association estimates), sensitiv-
ity analyses were performed, where different methods were used to detect possible pleiotropy and also to account 
for it:
 1) The MR-Egger regression: assesses directional pleiotropy by borrowing from the same principles of testing 
for small study bias in meta-analysis (causal estimate notated as βMR-Egger).
 2) The weighted median estimation method: Allows that up to 50% of the weight of genetic markers under 
analysis comes from invalid instruments and retains more power than MR-Egger.
 3) The exclusion of possible pleiotropic SNPs based on the gtx package in R (causal estimate notated as 
βMR-IVW_gtx).
 4) The exclusion of possible pleiotropic SNPs using a proxy search.
 5) For the lipids: the multivariable Mendelian randomization adjusting for the effect estimates of the other 
lipid phenotypes (causal estimate notated as βadjusted).
MR-Egger regression50 was used to investigate whether there is directional bias caused by pleiotropy. 
Directional bias means that the pleiotropic effects of genetic variants are not balanced about the null and are 
drawn into one direction. This regression is an adaption of the standard Egger regression which is used to analyze 
small study bias in the meta-analysis literature. The intercept obtained from the MR-Egger regression gives an 
estimate of directional bias and the slope coefficient provides an estimate of the causal effect, which is consistent 
even when all the genetic variants are invalid instrumental variables with respect to pleiotropy50. To assess 
whether the MR-Egger regression estimates might be biased through a violation of the NOME assumption, an 
adaption of the I² statistic I( )2GX 51 was calculated and the corrected MR-Egger estimate was computed using the 
method of Simulation Extrapolation (SIMEX)51.
Additionally to the MR-Egger regression, the weighted median estimator was calculated as proposed by 
Bowden et al.52. In this method, the ratio estimates of the SNP-exposure and SNP-outcome association estimates 
are ordered and weighted by the inverse of their variance. The weighted median estimator is then the median of 
these estimates, according to the weights. This estimator is consistent if at least 50% of the weight comes from 
valid instrumental variables. Although the MR-Egger regression method allows all the instrumental variables to 
be invalid, the weighted median estimation approach offers the advantages of an improved precision compared 
to the MR-Egger regression. Therefore, both methods were used to assess whether pleiotropy had influenced our 
results.
In two further sensitivity analyses, all SNPs that were assumed to have pleiotropic effects were excluded. In 
Mendelian randomization analyses, bias due to pleiotropy only occurs when the SNPs are associated with other 
phenotypes, which also influence the outcome variable or are independently associated with the outcome variable 
itself. If this is not the case and there is also no direct effect of the SNPs on the outcome variable, the effect of the 
SNPs on the outcome is mediated completely by the intermediate variable. Then, the causal effects of all SNPs indi-
vidually should rather be homogeneous and approximate the true unknown causal effect of the exposure variable 
on the outcome32, 53, 54. This assumption was tested by a goodness of fit test using the function “grs.filter.Qrs” in 
package “gtx” in R (Johnson, T.: Efficient Calculation for Multi-SNP Genetic Risk Scores. Poster presentation at the 
American Society of Human Genetics Annual Meeting, San Francisco, 2012). This function performs a stepwise 
downward model selection in which SNPs are iteratively removed from the risk score until the heterogeneity test is 
no longer significant at the specified threshold (pthreshold = 0.05). SNPs showing a deviation from this assumption are 
therefore potentially not mediated completely by the exposure and were excluded in a further sensitivity analysis. 
This was only the case, however, for one HDL-C SNP. In a second approach used to account for possible pleiotropy, 
we looked up whether there are either any overlapping SNPs in the different SNP selection datasets or SNPs in LD 
with each other. To find the proxies for each SNP, we used SNiPA55 with the 1000 Genomes Phase 3 v5 variant set 
and an LD-threshold of r² > 0.8. If overlaps were found, these SNPs were excluded. For the lipids, we followed two 
different approaches. First, we excluded all SNPs that were found in any other SNP selection dataset, no matter 
which trait. Second, we excluded only those SNPs that were found in other non-lipid SNP selection datasets (i.e. in 
the SNP selection for eGFR, BMI, WHR, FG and apoA-IV). In this case, an adjustment for the other lipid traits using 
multivariable Mendelian randomization was included as described below, to adjust for the lipid traits as well. This 
second approach was performed due to the huge SNP overlap between the different lipid traits.
For the lipid traits, we also performed a multivariable Mendelian randomization adjusting each lipid-apoA-IV 
causal estimate by the estimates of the SNP-lipids association not under consideration (i.e., when assessing the 
causal association between HDL-C and apoA-IV adjusting for LDL-C and TG associations with the same SNPs). 
For this, an extension to the inverse-variance weighted method was used, as proposed by Burgess et al.56, 57. In this 
approach the gene-outcome associations are regressed on all the gene-risk factor associations simultaneously in a 
multivariable regression model, using the SNPs associated with the risk factor of interest.
In the case where apoA-IV acted as the exposure variable, only two (for the lipids, eGFR, BMI and WHR) or 
three (for fasting glucose) SNPs were available for the MR analysis. Here, all four sensitivity analyses were not 
applicable or meaningful and therefore only the MR-IVW method was applied.
As four different “trait blocks” including correlated traits were analyzed, a p-value of 0.05/8 = 0.00625 was 
considered as significant.
LD structures and pairwise SNP correlations were retrieved from SNiPA (http://snipa.helmholtz-muenchen.
de/)55 using 1000 Genomes phase 3 data and superimposed to UCSC Genome Browser hg19 using modified 
scripts from58. Expression QTL data for rs964184 and for all genes in the APOA5-A4-C3-A1 (APOA5, APOA4, 
APOC3, APOA1, ZRP1/ZNF259, BUD13) cluster was retrieved from GTEx (www.gtexportal.org)59.
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